id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2011-N-0231-0004,FDA,FDA-2011-N-0231,"Agency Information Collection Activities; Proposals, Submissions, and Approvals",Notice,Notice of Approval,2011-11-25T05:00:00Z,2011,11,2011-11-25T05:00:00Z,,2011-11-25T14:16:51Z,2011-30326,0,0,0900006480f73634
FDA-2011-N-0231-0003,FDA,FDA-2011-N-0231,"Agency Information Collection Activities; Proposals, Submissions, and Approvals: Adverse Experience Reporting for Licensed Biological Products; and General Records",Notice,General Notice,2011-07-14T04:00:00Z,2011,7,2011-07-14T04:00:00Z,2011-08-16T03:59:59Z,2011-07-14T13:39:05Z,2011-17675,0,0,0900006480ec1c64
FDA-2011-N-0231-0001,FDA,FDA-2011-N-0231,"Agency Information Collection Activities; Proposals, Submissions, and Approvals: Adverse Experience Reporting for Licensed Biological Products and General Records",Notice,N-Notice,2011-04-21T04:00:00Z,2011,4,2011-04-21T04:00:00Z,2011-06-21T03:59:59Z,2011-04-21T13:59:28Z,2011-09651,0,0,0900006480c34c8b